LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Home・Akciju saraksts・Microbot Medical Inc

Microbot Medical Inc

Slēgts

4.06 3.84

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.81

Max

4.18

Galvenie mērījumi
By Trading Economics
Ienākumi	-899K -3.5M
Peļņas marža	-4,038.095
Darbinieki	20
EBITDA	-84K -3.5M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+131.96% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2025. g. 11. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	61M 189M
Iepriekšējā atvēršanas cena	0.22
Iepriekšējā slēgšanas cena	4.06

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

2.52 / 2.57 Atbalsts un pretestība

Microbot Medical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 27. aug. 22:51 UTC

Peļņas

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

2025. g. 27. aug. 23:57 UTC

Peļņas

Trip.com Group 1H Rev $4.01B

2025. g. 27. aug. 23:57 UTC

Peļņas

Trip.com Group 1H Adj EPS $1.84

2025. g. 27. aug. 23:57 UTC

Peļņas

Trip.com Group 1H EPS $1.82

2025. g. 27. aug. 23:50 UTC

Tirgus saruna

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

2025. g. 27. aug. 23:39 UTC

Peļņas

Correction to Nvidia Earnings Article -- WSJ

2025. g. 27. aug. 22:59 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 27. aug. 22:59 UTC

Tirgus saruna

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

2025. g. 27. aug. 22:58 UTC

Peļņas

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

2025. g. 27. aug. 22:57 UTC

Peļņas

South32 FY Free Cash Flow $192 Million

2025. g. 27. aug. 22:56 UTC

Peļņas

South32 FY Total Capital Expenditure $1.35 Billion

2025. g. 27. aug. 22:56 UTC

Peļņas

South32 FY Capital Expenditure $963 Million, Excluding EAIs

2025. g. 27. aug. 22:55 UTC

Peļņas

South32 Net Cash $123 Million at June 30

2025. g. 27. aug. 22:54 UTC

Peļņas

South32: Focused on Maintaining Strong Operating Momentum

2025. g. 27. aug. 22:53 UTC

Peļņas

South32: $144 Million Remains to be Returned to Shareholders Under Program

2025. g. 27. aug. 22:53 UTC

Peļņas

South32 Extends Capital Management Program for 12 Months

2025. g. 27. aug. 22:52 UTC

Peļņas

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

2025. g. 27. aug. 22:51 UTC

Peļņas

South32 FY Revenue $5.78 Billion, Up 17% On-Year

2025. g. 27. aug. 22:51 UTC

Peļņas

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

2025. g. 27. aug. 22:50 UTC

Peļņas

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

2025. g. 27. aug. 22:50 UTC

Peļņas

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

2025. g. 27. aug. 22:45 UTC

Peļņas

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

2025. g. 27. aug. 22:44 UTC

Peļņas

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

2025. g. 27. aug. 22:44 UTC

Peļņas

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

2025. g. 27. aug. 22:43 UTC

Peļņas

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

2025. g. 27. aug. 22:43 UTC

Peļņas

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

2025. g. 27. aug. 22:42 UTC

Peļņas

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

2025. g. 27. aug. 22:42 UTC

Peļņas

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

2025. g. 27. aug. 22:40 UTC

Peļņas

Sandfire Resources Net Debt $123 Million at June 30

2025. g. 27. aug. 22:40 UTC

Peļņas

Sandfire Resources FY Underlying Ebitda $527.7 Million

Salīdzinājums

Cenas izmaiņa

Microbot Medical Inc Prognoze

Cenas mērķis

By TipRanks

131.96% augšup

Prognoze 12 mēnešiem

Vidējais 9 USD 131.96%

Augstākais 9 USD

Zemākais 9 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

2.52 / 2.57Atbalsts un pretestība

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.